Search | Clinical Trials Finder

Conditions: Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease, CRC With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Interventions: GDC-6599, GDC-6599-matching placebo, Mannitol; Drug · Other · Diagnostic Test
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 8
States / cities: Los Angeles, California • Northridge, California • Coral Gables, Florida + 5 more

Conditions: Chronic Cough
Interventions: ADX-629, Placebo; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 14
States / cities: San Diego, California • San Jose, California • Hollywood, Florida + 11 more

Conditions: Chronic Cough (CC), Laryngeal Disease, Coughing
Interventions: Triamcinolone Acetonide Injectable Suspension, Saline injection; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Refractory Chronic Cough
Interventions: 3 mg NOC-100 (via nebulizer), 1 mg NOC-110 (via DPI) [1x 1 mg capsule], 3 mg NOC-110 (via DPI), Placebo (via DPI), 6 mg NOC-110 (via DPI), Placebo (via DPI) [2x Placebo capsules]; Drug
Lead sponsor: Nocion Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 3
States / cities: Phoenix, Arizona • Leesburg, Florida • Winter Park, Florida

Conditions: Refractory Chronic Cough
Interventions: 5 mg Serlopitant Tablets, Matching Placebo Tablets; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 29
States / cities: Los Angeles, California • Mission Viejo, California • San Diego, California + 24 more

Conditions: Head and Neck Cancer
Interventions: Barium Swallow, Questionnaires, Expiratory Muscle Strength Training (EMST) Device, Digital Manometer, Neurocognitive Exams, Barium; Procedure · Behavioral · Device + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: High-Flow Nasal Cannula; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 35 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Refractory Chronic Cough, Unexplained Chronic Cough, Cough Hypersensitivity
Interventions: Cough Management, CoughMonitor Suite; Behavioral · Device
Lead sponsor: Hyfe Inc; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Chronic Cough, OSA
Interventions: Straight CPAP, Sham CPAP; Device
Lead sponsor: Krishna M. Sundar; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cough
Interventions: Supra-threshold and progressive doses of diluted capsaicin via a dosimeter-controlled nebulizer, Saline; Biological
Lead sponsor: University of Montana; Other
Eligibility: 18 Years to 99 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Missoula, Montana

Conditions: Amyotrophic Lateral Sclerosis, Chronic Respiratory Failure, Airway Clearance Impairment, Neuromuscular Diseases
Interventions: Mechanical insufflation; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions: BAY1817080; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Cough
Interventions: Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer, Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer; Biological
Lead sponsor: University of Montana; Other
Eligibility: 18 Years to 99 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Missoula, Montana

Conditions: COPD
Interventions: biological/vaccine; Biological
Lead sponsor: University of South Florida; Other
Eligibility: 19 Years to 92 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Long COVID, Long Covid19, Post-COVID-19 Syndrome, Post Acute COVID-19 Syndrome, Dysautonomia, Anosmia, Dysgeusia, Brain Fog, Muscle Pain, Shortness of Breath, Dizziness, Fatigue Post Viral, Cough, Menstrual Cycle Abnormal, Pain
Interventions: Stellate Ganglion Block; Procedure
Lead sponsor: Metamorphosis LTD; Other
Eligibility: Not listed
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Cañon City, Colorado

Conditions: Interstitial Lung Disease
Interventions: Amitriptyline 25 MG, Amitriptyline 50 MG, Duloxetine 30 MG, Duloxetine 60 MG, Placebo 30 MG, Placebo 60 MG; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cough, Reflux
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Cough
Interventions: Gefapixant, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 15
States / cities: Phoenix, Arizona • Paramount, California • Springfield, Illinois + 12 more

Conditions: Chronic Cough
Interventions: Bradanicline, Placebo; Drug
Lead sponsor: Attenua, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 17
States / cities: La Mesa, California • Mission Viejo, California • Colorado Springs, Colorado + 12 more

Conditions: Smoking Cessation
Interventions: Nadolol, Placebo; Drug
Lead sponsor: Invion, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Phoenix, Arizona • Miami, Florida • St Louis, Missouri

Conditions: Chronic Cough (CC), Refractory Chronic Cough, Unexplained Chronic Cough
Interventions: BCS+inactive, BCS+active; Behavioral · Combination Product
Lead sponsor: University of Montana; Other
Eligibility: 18 Years to 99 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Aurora, Colorado • Atlanta, Georgia • Missoula, Montana

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Non-interventional study.; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 1,283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 47
States / cities: Highlands Ranch, Colorado • Wheat Ridge, Colorado • Clearwater, Florida + 43 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: cilomilast; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 115
States / cities: Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 103 more

Conditions: Pneumonia, Bronchiolitis, Asthma, Croup, Upper Respiratory Tract Infection, Lower Respiratory Tract Infection, Reactive Airway Disease
Interventions: Recording of Infants and Children's Cough Sounds; Other
Lead sponsor: ResApp Health Limited; Industry
Eligibility: 29 Days to 12 Years
Enrollment: 1,245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Boston, Massachusetts • Cleveland, Ohio • Houston, Texas

Search by objective public record fields.

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

Efficacy of Intramuscular Steroid Injection for Chronic Cough.

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough

Cough, Expiratory Training, and Chronic Aspiration After Head and Neck Radiotherapy

HFNC Effect on BCSS in Patients With COPD

Cough Management Wellness App for Refractory or Unexplained Chronic Cough

Sham CPAP vs. Straight CPAP for Chronic Cough

Cough Desensitization Therapy: Pilot 2

Mechanical Insufflation in the Philadelphia Amyotrophic Lateral Sclerosis Cohort (MI-PALS) Study

Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function

Cough Desensitization Therapy for Cough Hypersensitivity Syndrome

Human Safety of Capsaicin Inhalation Challenge Testing for Young and Older Men

Stellate Ganglion Block to Treat Long COVID 19 Case Series

Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough

Cough Monitoring Study

Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)

A Dose Escalation Study of Bradanicline in Refractory Chronic Cough

Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction

Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough

Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath

Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)

Diagnosing Respiratory Disease in Children Using Cough Sounds